Author

M. I. Samanovic

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 8 Microbiology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 9 Research Focus:host-pathogen & immune response· 9 Organism:human· 5 Organism:virus· 4 Assay:proteomics· 3 Approach:statistical model· 2 Organism:bacteria (other)· 1 Research Focus:benchmarking· 1

Frequent Co-Authors

M. J. Mulligan· 10 shared N. R. Landau· 7 shared T. Tada· 7 shared B. M. Dcosta· 6 shared H. Zhou· 6 shared A. Cornelius· 2 shared A. Koide· 2 shared K. A. Stapleford· 2 shared

Activity by Year

2018-2022 · peak 8/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

10 shared papersImmunology

M. J. Mulligan

Mutual co-authors in cluster

Author profile →

11 papers

Recent·Most cited

Inflammation durably imprints memory CD4+ T cells

S. L. Gray-Gaillard, S. Solis, H. Chen, C. Monteiro, G. Ciabattoni, M. I. Samanovic, A. R. Cornelius, T. Williams, E. Geesey, M. Rodriguez, M. B. Ortigoza, E. N. Ivanova, S. B. Koralov, M. J. Mulligan, R. S. Herati

This study compares transcriptional and epigenetic differences in Spike-specific CD4+ T cell memory between individuals primed by SARS-CoV-2 infection versus mRNA vaccination.

bioRxiv · Nov 15, 2022 · PreprintImmunology

Increased resistance of SARS-CoV-2 Omicron Variant to Neutralization by Vaccine-Elicited and Therapeutic Antibodies

T. Tada, H. Zhou, B. M. Dcosta, M. I. Samanovic, V. Chivukula, R. Herati, S. R. Hubbard, M. J. Mulligan, N. R. Landau

The paper assesses Omicron's resistance to vaccine and monoclonal antibody neutralization, finding boosters improve efficacy but existing therapies are largely ineffective.

bioRxiv · Dec 28, 2021Immunology

Neutralization of Mu and C.1.2 SARS-CoV-2 Variants by Vaccine-elicited Antibodies in Individuals With and Without Previous History of Infection

T. Tada, H. Zhou, B. M. Dcosta, M. I. Samanovic, A. Cornelius, R. Herati, M. J. Mulligan, N. R. Landau

This study evaluates neutralization of SARS-CoV-2 Mu and C.1.2 variants by vaccine-elicited and convalescent antibodies, finding that vaccine-induced responses remain protective despite partial resistance.

bioRxiv · Oct 19, 2021Immunology

Two-dimensional multiplexed assay for rapid and deep SARS-CoV-2 serology profiling and for machine learning prediction of neutralization capacity

A. Koide, T. Panchenko, C. Wang, S. A. Thannickal, L. A. Romero, K. W. Teng, F.-Z. Li, P. Akkapeddi, A. D. Corrado, J. Caro, C. Diefenbach, M. I. Samanovic, M. J. Mulligan, T. Hattori, K. A. Stapleford, , S. Koide

This paper introduces a 2D-MBBA assay for SARS-CoV-2 serology profiling and uses machine learning to predict neutralization capacity from antibody profiles.

bioRxiv · Aug 3, 2021 · PreprintImmunology

Comparison of Neutralizing Antibody Titers Elicited by mRNA and Adenoviral Vector Vaccine against SARS-CoV-2 Variants

T. Tada, H. Zhou, M. I. Samanovic, B. M. Dcosta, A. Cornelius, M. J. Mulligan, N. R. Landau

This study compares neutralizing antibody titers from mRNA and adenoviral vector vaccines against SARS-CoV-2 variants, finding lower neutralization against variants for Ad26.COV2.S and suggesting a second dose may improve protection.

bioRxiv · Jul 19, 2021Immunology

SARS-CoV-2 Lambda Variant Remains Susceptible to Neutralization by mRNA Vaccine-elicited Antibodies and Convalescent Serum

T. Tada, H. Zhou, B. M. Dcosta, M. I. Samanovic, M. J. Mulligan, N. R. Landau

This study assesses the neutralization efficacy of convalescent sera and mRNA vaccine-elicited antibodies against the SARS-CoV-2 lambda variant, finding minimal reduction in neutralizing titers.

bioRxiv · Jul 2, 2021 · PreprintImmunology

The Spike Proteins of SARS-CoV-2 B.1.617 and B.1.618 Variants Identified in India Provide Partial Resistance to Vaccine-elicited and Therapeutic Monoclonal Antibodies.

T. Tada, H. Zhou, B. M. Dcosta, M. I. Samanovic, M. J. Mulligan, N. R. Landau

This study evaluates the neutralization resistance of SARS-CoV-2 B.1.617 and B.1.618 spike proteins to vaccine-elicited and therapeutic antibodies, finding partial resistance due to specific mutations.

bioRxiv · May 14, 2021Immunology

Optimized Quantification of Intrahost Viral Diversity in SARS-CoV-2 and Influenza Virus Sequence Data

A. Roder, K. E. Johnson, M. Knoll, M. Khalfan, B. Wang, S. Schultz-Cherry, S. Banakis, A. Kreitman, C. Mederos, J.-H. Youn, R. Mercado, W. Wang, D. Ruchnewitz, M. I. Samanovic, M. J. Mulligan, , E. Ghedin

This study evaluates variant calling tools for detecting minority variants in viral sequencing data and provides guidance for accurate quantification of intrahost viral diversity.

bioRxiv · May 5, 2021 · PreprintMicrobiology

B.1.526 SARS-CoV-2 variants identified in New York City are neutralized by vaccine-elicited and therapeutic monoclonal antibodies

H. Zhou, B. M. Dcosta, M. I. Samanovic, M. J. Mulligan, N. R. Landau, T. Tada

The paper assesses neutralization of B.1.526 SARS-CoV-2 variants by vaccine-elicited and therapeutic antibodies, finding minimal impact on neutralizing titers.

bioRxiv · Mar 24, 2021Immunology

High titers of multiple antibody isotypes against the SARS-CoV-2 spike receptor-binding domain and nucleoprotein associate with better neutralization.

M. G. Noval, M. E. Kaczmarek, A. Koide, B. A. Rodriguez-Rodriguez, P. Louie, T. Tada, T. Hattori, T. Panchenko, L. A. Romero, K. W. Teng, A. Bazley, M. de Vries, M. I. Samanovic, J. N. Weiser, I. Aifantis, , K. A. Stapleford

The paper assesses neutralization capacity and antibody titers against SARS-CoV-2 antigens in recovered healthcare workers, finding that high titers of multiple isotypes correlate with neutralization.

bioRxiv · Aug 15, 2020 · PreprintMicrobiology

Cytokinin signaling in Mycobacterium tuberculosis

M. I. Samanovic, H.-C. Hsu, M. B. Jones, V. Jones, M. R. McNeil, S. H. Becker, A. T. Jordan, M. Strnad, C. Xu, M. Jackson, H. Li, K. H. Darwin

This study shows Mycobacterium tuberculosis uses cytokinins, previously known as plant hormones, to induce gene expression affecting its cell envelope.

bioRxiv · Jan 18, 2018Microbiology